Over the past year, BioAmber Inc. has successfully applied its breakthrough succinic acid purification process to adipic acid. Through the licensing deal with CELEXION, BioAmber will leverage its succinic know-how, infrastructure, partnerships and customer base to accelerate the development of biobased adipic acid. BioAmber Inc. has also established a state of the art research and development facility in Plymouth, Minnesota with capabilities in molecular biology, fermentation and analytical chemistry to support its adipic acid program.
“CELEXION’s technology is a perfect fit for the leadership we have developed in commercializing biobased succinic acid,” said Jean-Francois Huc, CEO of BioAmber Inc.. “CELEXION’s highly attractive metabolic pathway, coupled with our novel purification process and scale-up capabilities, gives us a clear path to biobased adipic acid that, like our biobased succinic, is lower cost and has a better environmental footprint than the current petroleum route.”
“Renewable chemicals such as biobased adipic acid will become critical building blocks of the future economy. Given BioAmber Inc.’s leadership position in succinic acid and the natural extension of their assets to adipic acid, we are very pleased to partner with BioAmber Inc. for commercialization of our adipic acid technology,” said Dr. Brian M. Baynes, CEO of CELEXION.
About BioAmber Inc.
BioAmber Inc. is a US registered renewable chemistry company with an extensive IP portfolio and know-how covering the production, purification and use of biobased succinic acid and derivatives including modified PBS, a biodegradable polymer with superior heat resistance and processability. BioAmber Inc. has the world’s first dedicated biobased succinic acid plant and has partnerships with market leaders Cargill, Mitsui & Co and DuPont Applied Biosciences. The company’s head office is located in Montreal, Canada, with research labs in Minneapolis, MN, a sales office in Shanghai, China and a production plant in Pomacle, France.
CELEXION LLC is a bioengineering company that develops powerful platform technologies and products for partners in the pharmaceutical, industrial, agricultural, and life science research sectors. The company’s technologies include the SECANT platform for engineering high performance protein roducts, a billion-member library of human IgG antibodies for biotherapeutic lead generation, enzymatic pathways for synthesis of a variety of high-value materials from wastes and other inexpensive precursors, a novel family of enzymes for manipulation of chromosome-sized DNA, as well as a variety of other tools. The company is based in Cambridge, MA, USA and financed by Flagship Ventures and GE Healthcare Financial Services. For further information, please visit our website at www.celexionbio.com.
CELEXION is a registered trademark and SECANT is a pending trademark application of Celexion LLC.
Media Contact (BioAmber Inc.)
Phone: +1 202 470 3239 or +32 496 116198
Media Contact (CELEXION)
Phone: +1(617) 500-3011 ext. 504